• Armata received USD 3.7 million in additional non-dilutive funding from the U.S. Department of War for AP-SA02 Phase 3 development.
• Total Department of War support for the AP-SA02 program rises to about USD 32.4 million.
• Funds support Phase 3 work in complicated Staphylococcus aureus bacteremia, with AP-SA02 positioned as an adjunctive therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Armata Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609230700PR_NEWS_USPR_____LA54741) on September 23, 2026, and is solely responsible for the information contained therein.